IMFINZI (durvalumab) Granted Priority Review and Breakthrough Therapy Designation in the US for Patients With Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers
July 29, 2025
July 29, 2025
WILMINGTON, Delaware, July 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
IMFINZI (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit
If appro . . .
* * *
IMFINZI (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit
If appro . . .